Nicholas DeVito, Assistant Professor of Medicine at Duke University, Division of Medical Oncology, shared a post on LinkedIn:
“Stellar results from Bot/Bal in MSS colorectal cancer – an immunotherapy combo I have been excited about since data presented at SITC 2022 which inspired our first-line trial with these agents.
It is a thrilling time to be a GI oncologist where the age of immunotherapy in these cancers has arrived.”